Malignant thymoma: current status of classification and multimodality treatment
- 11 February 2003
- journal article
- review article
- Published by Springer Nature in Annals of Hematology
- Vol. 82 (2) , 69-76
Abstract
Classification, understanding of the pathophysiology, and treatment options of thymoma have changed during recent years. It is hoped that novel strategies will lead to a survival benefit in these patients. It has become clear that patients with thymoma are best treated with multimodality therapy. In this review, a pathologist, an immunologist, a surgeon, a radiotherapist, a pneumologist, and oncologists discuss the current status of classification and strategies for the treatment of patients with thymoma.Keywords
This publication has 69 references indexed in Scilit:
- New WHO histologic classification predicts prognosis of thymic epithelial tumorsCancer, 2002
- Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?Neurology, 2001
- Effects of adenoviral wild-type p53 gene transfer in p53 -mutated lymphoma cellsCancer Gene Therapy, 2001
- Malignant Thymoma With Metastases to the Gastrointestinal Tract and OvaryAmerican Journal of Clinical Oncology, 2000
- Preoperative radiotherapy and surgery for advanced thymoma with invasion to the great vesselsJournal of Surgical Oncology, 1996
- Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy.Journal of Clinical Oncology, 1994
- EST 2582 Phase II Trial of Cisplatin in Metastatic or Recurrent ThymomaAmerican Journal of Clinical Oncology, 1993
- Effectiveness of interleukin-2 in invasive lymphoepithelial thymomaThe Lancet, 1990
- The management of malignant thymoma with radiation therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1979
- Thymoma: Factors Influencing PrognosisSurgical Clinics of North America, 1973